Clinical Trials Logo

HER2-expression clinical trials

View clinical trials related to HER2-expression.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT02226757 Not yet recruiting - NSCLC Clinical Trials

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Start date: August 2014
Phase: Phase 2
Study type: Interventional

This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent. Patients will be treated with weekly paclitaxel-trastuzumab.